| abstract |
A novel chimeric antigen receptor (CAR) is provided. When the CARs herein are expressed on the surface of immune cells, such immune cells can be directed to osteosarcoma cells, as demonstrated by our in vivo data. In a mouse intraperitoneal model, tumor growth was significantly delayed in T cells expressing CAR containing scFv from TP1 or TP3 antibody. The CAR-expressing immunocytes herein have shown therapeutic effects in a mouse model simulating metastatic osteosarcoma in a manner that reduces tumor volume. Combined with the finding that hepatocytes from healthy bone marrow are not significantly affected by any CAR-expressing T cells, the present disclosure provides an attractive alternative cell therapy for the treatment of osteosarcoma. |